Drug intelligence / Profile preview

TLM-102

Development stage: Unknown
Lead developer: TLM

Overview

TLM-102 is an investigational Therillume pipeline drug being developed for **Neurofibromatosis Type 1**. Publicly available information identified from the company pipeline indicates that it is a **Phase 1** program for NF1, but the specific active substance, molecular target, modality, route, and mechanism of action have not been publicly disclosed in the source material reviewed. Therillume is described as a division of Recombinetics, and TLM-102 appears to be one of the company's named NF1 development candidates.

Other names: TLM-102-TLM-Neurofibromatosis Type 1 (NF1)

Beyond the preview

Go deeper on TLM-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLM-102.

Explore the full profile